Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical Co Ltd (SNPHF)
OTHER OTC:SNPHF
RESEARCH TOOLSreports
SNPHF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.11 - $14.98
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
$3.32B
Enterprise Value$510.34B
Total Cash (Recent Filing)¥77.85B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)19.1
Beta0.09
Next Earnings
May 13, 2025EPS Estimate
0.13Last Dividend Ex-Date
Mar 28, 2025Dividend Yield2.43%
Share Statistics
EPS (TTM)0.51
Shares Outstanding342,050,570
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.12Price Target Upside59.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Santen Pharmaceutical Co News
PremiumCompany Announcements
Santen Pharmaceutical Co. Revises Year-End Dividend Forecast
PremiumCompany Announcements
Santen Pharmaceutical to Cancel 5 Million Treasury Shares
PremiumCompany Announcements
Santen Pharmaceutical Reports Financial Results and Strategic Initiatives
PremiumCompany Announcements
Santen Pharmaceutical Completes Strategic Share Buyback
PremiumCompany Announcements
Santen Pharmaceutical’s Strategic Share Buyback Update
PremiumCompany Announcements
Santen Pharmaceutical Co. Reports Mixed Financial Results---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
7.87% Mutual Funds
― Other Institutional Investors
85.94% Public Companies and
Individual Investors
SNPHF FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was $8.11 and its highest was $14.98 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is $3.32B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is May 13, 2025 which is in 34 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Feb 06, 2025. The company reported $0.173 earnings per share for the quarter, missing the consensus estimate of $0.179 by -$0.005.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Annually dividend of $0.117 which represents an annual dividend yield of 2.43%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 0.13.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 342,050,570 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of $0.173 in its last earnings report, missing expectations of $0.179. Following the earnings report the stock price went down -3.064%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in SNPHF
---
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
---
SNPHF Stock 12 Month Forecast
Average Price Target
$15.12
▲(59.66% Upside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Sumitomo Dainippon Pharma Co
―
ONO Pharmaceutical Co
―
Takeda Pharmaceutical Co
―
Best Analysts Covering SNPHF
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-6.50%
reiterated a buy rating last month
Copying Seiji Wakao's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -6.50% per trade.
---